Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma

Carrie C. Lubitz, Lucia De Gregorio, Abbey L. Fingeret, Konstantinos P. Economopoulos, Diana Termezawi, Mursal Hassan, Sareh Parangi, Antonia E. Stephen, Elkan F. Halpern, Karen Donelan, J. Shannon Swan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Thyroid cancer incidence is increasing. The effect of diagnosis and treatment on health-related quality of life (HRQoL) is an essential variable in the absence of a change in life span for the majority of patients. HRQoL instruments, with data useful for between-disease comparisons, are being increasingly used for health policy and outcomes evaluation. Variation exits among the instruments based on the impact of a specific disease. We assessed which of four well-validated, preference-based surveys detect changes in health and clinical intervention in patients diagnosed with papillary thyroid cancer (PTC). Methods: Four commonly used HRQoL questionnaires (Short Form-12v2® [SF6D], EuroQol-5D [EQ5D], and Health Utilities Index Mark 2 and 3 [HUI2, HUI3]) were administered to patients with the diagnosis of PTC at three perioperative time points during the first year of treatment. Clinicopathological and treatment course data were assessed for HRQoL impact including complications from surgery, re-operation for persistence/early recurrence, and adjuvant radioactive iodine treatment. We compared standard metrics, including ceiling effect, intraclass correlation coefficient, effect sizes, and quality-adjusted life-years between the four instruments. Results: Of 117 patients, 27% had a preoperative diagnosis of anxiety or depression, 41% had regional lymph node metastases, three had distant metastases and 49% underwent adjuvant radioactive iodine treatment. The ceiling effect (i.e., proportion with a perfect score) was greatest with EQ5D and least with SF6D. Index scores ranged from 0.77 (SF6D) to 0.90 (EQ5D). All scores declined at two weeks postoperatively and returned to pretreatment levels at six months. The SF6D was the only instrument to exceed the conventional minimally important difference between all three time points. Quality-adjusted life-years were as follows: SF6D, 0.79; EQ5D, 0.90; HUI2, 0.88; and HUI3, 0.86. Conclusions: Our results reflect the general good health of PTC patients. The effect on quality of life is primarily related to emotional and social impacts of treatment. The results support the measurement of a similar underlying construct, although variation in detecting changes in health exists between the instruments. Of the instruments assessed, the SF6D is the most responsive to treatment effects and should be utilized in future economic analyses in this patient population.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalThyroid
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Quality of Life
Quality-Adjusted Life Years
Health
Iodine
Therapeutics
Neoplasm Metastasis
Health Policy
Papillary Thyroid cancer
Social Change
Thyroid Neoplasms
Anxiety
Lymph Nodes
Economics
Depression
Recurrence
Incidence
Population
Surveys and Questionnaires

Keywords

  • clinical research
  • quality of life
  • surgery
  • thyroid cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. / Lubitz, Carrie C.; De Gregorio, Lucia; Fingeret, Abbey L.; Economopoulos, Konstantinos P.; Termezawi, Diana; Hassan, Mursal; Parangi, Sareh; Stephen, Antonia E.; Halpern, Elkan F.; Donelan, Karen; Swan, J. Shannon.

In: Thyroid, Vol. 27, No. 2, 01.02.2017, p. 197-206.

Research output: Contribution to journalArticle

Lubitz, CC, De Gregorio, L, Fingeret, AL, Economopoulos, KP, Termezawi, D, Hassan, M, Parangi, S, Stephen, AE, Halpern, EF, Donelan, K & Swan, JS 2017, 'Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma', Thyroid, vol. 27, no. 2, pp. 197-206. https://doi.org/10.1089/thy.2016.0260
Lubitz, Carrie C. ; De Gregorio, Lucia ; Fingeret, Abbey L. ; Economopoulos, Konstantinos P. ; Termezawi, Diana ; Hassan, Mursal ; Parangi, Sareh ; Stephen, Antonia E. ; Halpern, Elkan F. ; Donelan, Karen ; Swan, J. Shannon. / Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. In: Thyroid. 2017 ; Vol. 27, No. 2. pp. 197-206.
@article{25fe0091b9ec4bf5919ca7b6c4510f48,
title = "Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma",
abstract = "Background: Thyroid cancer incidence is increasing. The effect of diagnosis and treatment on health-related quality of life (HRQoL) is an essential variable in the absence of a change in life span for the majority of patients. HRQoL instruments, with data useful for between-disease comparisons, are being increasingly used for health policy and outcomes evaluation. Variation exits among the instruments based on the impact of a specific disease. We assessed which of four well-validated, preference-based surveys detect changes in health and clinical intervention in patients diagnosed with papillary thyroid cancer (PTC). Methods: Four commonly used HRQoL questionnaires (Short Form-12v2{\circledR} [SF6D], EuroQol-5D [EQ5D], and Health Utilities Index Mark 2 and 3 [HUI2, HUI3]) were administered to patients with the diagnosis of PTC at three perioperative time points during the first year of treatment. Clinicopathological and treatment course data were assessed for HRQoL impact including complications from surgery, re-operation for persistence/early recurrence, and adjuvant radioactive iodine treatment. We compared standard metrics, including ceiling effect, intraclass correlation coefficient, effect sizes, and quality-adjusted life-years between the four instruments. Results: Of 117 patients, 27{\%} had a preoperative diagnosis of anxiety or depression, 41{\%} had regional lymph node metastases, three had distant metastases and 49{\%} underwent adjuvant radioactive iodine treatment. The ceiling effect (i.e., proportion with a perfect score) was greatest with EQ5D and least with SF6D. Index scores ranged from 0.77 (SF6D) to 0.90 (EQ5D). All scores declined at two weeks postoperatively and returned to pretreatment levels at six months. The SF6D was the only instrument to exceed the conventional minimally important difference between all three time points. Quality-adjusted life-years were as follows: SF6D, 0.79; EQ5D, 0.90; HUI2, 0.88; and HUI3, 0.86. Conclusions: Our results reflect the general good health of PTC patients. The effect on quality of life is primarily related to emotional and social impacts of treatment. The results support the measurement of a similar underlying construct, although variation in detecting changes in health exists between the instruments. Of the instruments assessed, the SF6D is the most responsive to treatment effects and should be utilized in future economic analyses in this patient population.",
keywords = "clinical research, quality of life, surgery, thyroid cancer",
author = "Lubitz, {Carrie C.} and {De Gregorio}, Lucia and Fingeret, {Abbey L.} and Economopoulos, {Konstantinos P.} and Diana Termezawi and Mursal Hassan and Sareh Parangi and Stephen, {Antonia E.} and Halpern, {Elkan F.} and Karen Donelan and Swan, {J. Shannon}",
year = "2017",
month = "2",
day = "1",
doi = "10.1089/thy.2016.0260",
language = "English (US)",
volume = "27",
pages = "197--206",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma

AU - Lubitz, Carrie C.

AU - De Gregorio, Lucia

AU - Fingeret, Abbey L.

AU - Economopoulos, Konstantinos P.

AU - Termezawi, Diana

AU - Hassan, Mursal

AU - Parangi, Sareh

AU - Stephen, Antonia E.

AU - Halpern, Elkan F.

AU - Donelan, Karen

AU - Swan, J. Shannon

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Thyroid cancer incidence is increasing. The effect of diagnosis and treatment on health-related quality of life (HRQoL) is an essential variable in the absence of a change in life span for the majority of patients. HRQoL instruments, with data useful for between-disease comparisons, are being increasingly used for health policy and outcomes evaluation. Variation exits among the instruments based on the impact of a specific disease. We assessed which of four well-validated, preference-based surveys detect changes in health and clinical intervention in patients diagnosed with papillary thyroid cancer (PTC). Methods: Four commonly used HRQoL questionnaires (Short Form-12v2® [SF6D], EuroQol-5D [EQ5D], and Health Utilities Index Mark 2 and 3 [HUI2, HUI3]) were administered to patients with the diagnosis of PTC at three perioperative time points during the first year of treatment. Clinicopathological and treatment course data were assessed for HRQoL impact including complications from surgery, re-operation for persistence/early recurrence, and adjuvant radioactive iodine treatment. We compared standard metrics, including ceiling effect, intraclass correlation coefficient, effect sizes, and quality-adjusted life-years between the four instruments. Results: Of 117 patients, 27% had a preoperative diagnosis of anxiety or depression, 41% had regional lymph node metastases, three had distant metastases and 49% underwent adjuvant radioactive iodine treatment. The ceiling effect (i.e., proportion with a perfect score) was greatest with EQ5D and least with SF6D. Index scores ranged from 0.77 (SF6D) to 0.90 (EQ5D). All scores declined at two weeks postoperatively and returned to pretreatment levels at six months. The SF6D was the only instrument to exceed the conventional minimally important difference between all three time points. Quality-adjusted life-years were as follows: SF6D, 0.79; EQ5D, 0.90; HUI2, 0.88; and HUI3, 0.86. Conclusions: Our results reflect the general good health of PTC patients. The effect on quality of life is primarily related to emotional and social impacts of treatment. The results support the measurement of a similar underlying construct, although variation in detecting changes in health exists between the instruments. Of the instruments assessed, the SF6D is the most responsive to treatment effects and should be utilized in future economic analyses in this patient population.

AB - Background: Thyroid cancer incidence is increasing. The effect of diagnosis and treatment on health-related quality of life (HRQoL) is an essential variable in the absence of a change in life span for the majority of patients. HRQoL instruments, with data useful for between-disease comparisons, are being increasingly used for health policy and outcomes evaluation. Variation exits among the instruments based on the impact of a specific disease. We assessed which of four well-validated, preference-based surveys detect changes in health and clinical intervention in patients diagnosed with papillary thyroid cancer (PTC). Methods: Four commonly used HRQoL questionnaires (Short Form-12v2® [SF6D], EuroQol-5D [EQ5D], and Health Utilities Index Mark 2 and 3 [HUI2, HUI3]) were administered to patients with the diagnosis of PTC at three perioperative time points during the first year of treatment. Clinicopathological and treatment course data were assessed for HRQoL impact including complications from surgery, re-operation for persistence/early recurrence, and adjuvant radioactive iodine treatment. We compared standard metrics, including ceiling effect, intraclass correlation coefficient, effect sizes, and quality-adjusted life-years between the four instruments. Results: Of 117 patients, 27% had a preoperative diagnosis of anxiety or depression, 41% had regional lymph node metastases, three had distant metastases and 49% underwent adjuvant radioactive iodine treatment. The ceiling effect (i.e., proportion with a perfect score) was greatest with EQ5D and least with SF6D. Index scores ranged from 0.77 (SF6D) to 0.90 (EQ5D). All scores declined at two weeks postoperatively and returned to pretreatment levels at six months. The SF6D was the only instrument to exceed the conventional minimally important difference between all three time points. Quality-adjusted life-years were as follows: SF6D, 0.79; EQ5D, 0.90; HUI2, 0.88; and HUI3, 0.86. Conclusions: Our results reflect the general good health of PTC patients. The effect on quality of life is primarily related to emotional and social impacts of treatment. The results support the measurement of a similar underlying construct, although variation in detecting changes in health exists between the instruments. Of the instruments assessed, the SF6D is the most responsive to treatment effects and should be utilized in future economic analyses in this patient population.

KW - clinical research

KW - quality of life

KW - surgery

KW - thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=85011392372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011392372&partnerID=8YFLogxK

U2 - 10.1089/thy.2016.0260

DO - 10.1089/thy.2016.0260

M3 - Article

C2 - 27824301

AN - SCOPUS:85011392372

VL - 27

SP - 197

EP - 206

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 2

ER -